On behalf of MCHRI Leadership & Faculty Director Dr. Gary Shaw

Dear Colleagues,

Through the support of a generous philanthropic donation, MCHRI is pleased to offer the new Drug & Device Development (D³) Training Program. The D³ Training Program has been designed with the goal of providing individuals an engaging and stimulating experience that sparks interest and cultivates skills in the translational medicine field and, in the process, develops clinical researchers with expertise in the development of novel therapeutics and diagnostics in pregnant women and children.

The training program will have opportunities for in-person, hybrid, and virtual experiences and applicable to applicants with little to no prior experience in this field. The program focus is a 4-week full-time, ‘internship’ within an industry partner. This year’s industry partners include Bayer, BridgeBio Pharma, Dexcom, Genentech, GlaxoSmithKlein, Horizon Therapeutics, Intuitive Surgical, Ionis, Pfizer, and Revelation Biosciences.

The program will be able to accommodate at least (10) slots for the Fall cycle. Awarded individuals will have the opportunity to gain insight into a variety of settings including experience with global pharmaceutical companies, medical device manufacturers, and startups.

Program features include:
- Orientation focusing on expectations, goals, and curriculum
- Connected experience within an industry partner’s operations
  - Interact with project team members from different major functional areas
  - Participate directly with one or more project teams
  - Assist with the advancement of a novel therapeutic or diagnostic development project as needed (protocol development, study design, statistical considerations, regulatory document preparation, regulatory interactions and strategy, review of literature, etc.)
- Support and guidance during the program by a Stanford Faculty Advisor
- As a final deliverable, the awardee will be asked to present a Target Product Profile (TPP) or describe what you learned during the training (to be pre-approved by course leadership) at a Stanford MCHRI educational seminar shortly after training completion.

Eligibility
Residents, Clinical Fellows (MD or MD, PhD)*, Instructors, and Faculty who are able to complete the 4-week experience in four 1-week blocks, two 2-week blocks, or one 4-week block within a 4 month timeframe from a projected start date of November 1, 2022.

*The Stanford School of Medicine, Department of Graduate Medical Education (GME) Committee has approved the D³ Training Program as an elective to fulfill a portion of the fellow’s training.

Apply
To apply for the program, please submit the following as a compiled PDF document via email by Sunday, October 2, 2022 to jli2022@stanford.edu:
- 1-page personal statement
- Applicant’s NIH Biosketch or CV
- Letter of Nomination** from Department Chair, Division Chief or Training Program Director
  - **Letter must include commitment of salary support during the internship period

Award
Each training engagement may have specific costs associated to the format (virtual, hybrid, in-person). The program has funding available for travel and other expenditures. Each training scenario will be evaluated once the awarded applicant and industry site location are matched. Any awarded funds will be provided via formal Notice of Award with the awardee’s financial representative responsible for reconciliation of proposed expenditures to award budget.

For more information on how to apply and program details, check out our website. Please be advised that applications must be submitted by Sunday, October 2, 2022 at 5:00pm (PT).

Contact
Please contact Grant Wells at jli2022@stanford.edu for any questions.